PremiumCompany AnnouncementsscPharmaceuticals Reports Strong Revenue Growth in 2024 scPharmaceuticals reports Q 4EPS (35c), consensus (39c) Options Volatility and Implied Earnings Moves Today, March 19, 2025 PremiumThe FlyscPharmaceuticals reports preliminary Q4 FUROSCIX revenue $12M-$12.3M scPharmaceuticals price target lowered to $12 from $16 at Craig-Hallum scPharmaceuticals Reports Strong Growth in Q3 2024 PremiumThe FlyscPharmaceuticals sells 12M shares at $4.00 in public offering scPharmaceuticals Secures Funding, Advances FUROSCIX Commercialization scPharmaceuticals reports $125M non-dilutive financings with Perceptive Advisors 
